Ironwood backs FY25 revenue view $290M-$310M, consensus $306.97M

1 day ago 5

TipRanks

Sat, January 3, 2026 astatine 6:20 AM CST 1 min read

Backs FY25 adjusted EBITDA presumption greater than $135M. “Throughout 2025, we made important advancement successful maximizing LINZESS portion delivering sustained profits and currency flows successful an effort to fortify our fiscal presumption and support compliance with indebtedness covenants implicit the coming quarters,” said Tom McCourt, main enforcement serviceman of Ironwood (IRWD). “As we adjacent 2025, we are connected way to execute the low-end of our full-year LINZESS U.S. nett income and full gross guidance ranges and ended the 4th fourth with greater than $200 cardinal successful currency and currency equivalents. Also, successful the 4th fourth we met with the FDA to align connected a confirmatory Phase 3 proceedings plan of apraglutide for the attraction of abbreviated bowel syndrome with intestinal failure. Based connected this meeting, we are connected way to initiate a confirmatory proceedings successful the archetypal fractional of 2026 and expect to supply details connected the proceedings plan successful our 4th fourth and full-year 2025 update aboriginal this quarter.”

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See Insiders’ Hot Stocks connected TipRanks >>

Read More connected IRWD:

Disclaimer & DisclosureReport an Issue

Ironwood Pharma Resolves Ferring Dispute, Amends License Terms
Ironwood terms people raised to $3.80 from $1.70 astatine Craig-Hallum
Ironwood Pharma’s LINZESS® Price Set by HHS
Ironwood Pharmaceuticals Reports Strong Q3 2025 Earnings
Midday Fly By: Insurers gaffe arsenic Senate spending measure lacks ACA extension

Read Entire Article